Efeitos adversos agudos de medicações utilizadas na psiquiatria
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2024.221674Palavras-chave:
Efeitos adversos, Lítio, Ácido valproico, Antipsicóticos, PsiquiatriaResumo
Todas as medicações utilizadas apresentam risco de efeitos adversos, não sendo diferente na psiquiatria. Dentre tais efeitos, alguns podem fazer o paciente procurar atendimento médico e podem, inclusive, ser potencialmente fatais. Neste artigo, abordaremos alguns efeitos adversos importantes de medicações psiquiátricas com os quais o médico pode se deparar na sua prática clínica.
Downloads
Referências
Haddad PM, Barnes TER. Good Clinical Practice in Psychopharmacology. In: Haddad PM, Nutt DJ, editors. Seminars in Clinical Psychopharmacology. 3rd ed. New York: Cambridge University Press; 2020. p. 203–26.
J. F. Cade. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2:349–52.
Cogen PH, Whybrow PC. Lithium: a fascinating element in neuropsychiatry. In: Bauer M, Grof P, Muller-Oerlinghausen B, editors. Lithium in Neuropsychiatry: The Comprehensive Guide. London: Informa Healthcare; 2006.
Marwood L, Taylor R, Goldsmith K, Romeo R, Holland R, Pickles A, et al. Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study). BMC Psychiatry. 2017 Dec 26;17(1):231.
Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M. Role of Lithium Augmentation in the Management of Major Depressive Disorder. CNS Drugs. 2014 Apr 5;28(4):331–42.
Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013 Jun 27;346(jun27 4):f3646–f3646.
Alda M. Lithium in the treatment of bipolar disorder: Pharmacology and pharmacogenetics. Vol. 20, Molecular Psychiatry. Nature Publishing Group; 2015. p. 661–70.
Taylor, David, Barnes, Thomas E, Young, Allan. The Maudsley Prescribing Guidelines in Psychiatry.
Finley PR. Drug Interactions with Lithium: An Update. Clin Pharmacokinet. 2016 Aug 2;55(8):925–41.
Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord. 2016 Dec 17;4(1):27.
Wilting I, Heerdink ER, Mersch PPA, den Boer JA, Egberts ACG, Nolen WA. Association between lithium serum level, mood state, and patient-reported adverse drug reactions during long-term lithium treatment: a naturalistic follow-up study. Bipolar Disord. 2009 Jun;11(4):434–40.
Oruch R, Elderbi MA, Khattab HA, Pryme IF, Lund A. Lithium: A review of pharmacology, clinical uses, and toxicity. Eur J Pharmacol. 2014 Oct 5;740:464–73.
Gerrett D, Lamont T, Paton C, Barnes TRE, Shah A. Prescribing and monitoring lithium therapy: summary of a safety report from the National Patient Safety Agency. BMJ. 2010 Nov 19;341(nov19 1):c6258–c6258.
Baird-Gunning J, Lea-Henry T, Hoegberg LCG, Gosselin S, Roberts DM. Lithium Poisoning. J Intensive Care Med. 2017 May 11;32(4):249–63.
Hansen HE, Amdisen A. Lithium intoxication. (Report of 23 cases and review of 100 cases from the literature). Q J Med . 1978;123–44.
Haussmann R, Bauer M, von Bonin S, Grof P, Lewitzka U. Treatment of lithium intoxication: facing the need for evidence. Int J Bipolar Disord. 2015 Dec 22;3(1):23.
Yatham LN, Kennedy SH, Parikh S v, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97–170.
Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand. 2006 Jul;114(1):1–7.
Carr RB, Shrewsbury K. Hyperammonemia Due to Valproic Acid in the Psychiatric Setting. American Journal of Psychiatry. 2007 Jul;164(7):1020–7.
Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cellular and Molecular Life Sciences. 2007 Aug 18;64(16):2090–103.
Cheng M, Tang X, Wen S, Yue J, Wang H. Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012. Compr Psychiatry. 2013 Jul;54(5):562–7.
Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014 Feb 19;348(feb19 6):g1626–g1626.
Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin Syndrome. J Clin Psychopharmacol. 2015 Aug;35(4):382–8.
Maitland S, Baker M. Serotonin syndrome. Drug Ther Bull. 2022 Jun;60(6):88–91.
Boyer EW, Shannon M. The Serotonin Syndrome. New England Journal of Medicine. 2005 Mar 17;352(11):1112–20.
Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003 Sep 1;96(9):635–42.
Gillman PK. The serotonin syndrome and its treatment. Journal of Psychopharmacology. 1999 Jan 2;13(1):100–9.
Tormoehlen LM, Rusyniak DE. Neuroleptic malignant syndrome and serotonin syndrome. In 2018. p. 663–75.
Wang RZ, Vashistha V, Kaur S, Houchens NW. Serotonin syndrome: Preventing, recognizing, and treating it. Cleve Clin J Med. 2016 Nov;83(11):810–6.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association Publishing; 2022.
Strawn JR, Keck PE, Caroff SN. Neuroleptic Malignant Syndrome. American Journal of Psychiatry. 2007 Jun;164(6):870–6.
Tse L, Barr A, Scarapicchia V, Vila-Rodriguez F. Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective. Curr Neuropharmacol. 2015 Jul 14;13(3):395–406.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2024 Raphael Antonio Medeiros de Castro, Cristina Marta Del-Ben
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
